Prescient Therapeutics welcomes James McDonnell as Chief Executive Officer

MELBOURNE Australia, 17 December 2024: Prescient Therapeutics Limited (Company; ASX: PTX), a clinical stage oncology company developing personalised therapies for cancer, is pleased to announce the appointment of James McDonnell as Chief Executive Officer, effective 20 January 2025.

Mr McDonnell is an accomplished senior biopharmaceutical leader with over 25 years of experience in the global pharmaceutical industry, including significant involvement in blood disorders and hematological malignancies such as Myeloma, Myelodysplasia, and CML. His strategic vision and leadership have been instrumental in delivering exceptional commercial results complemented by his ability to build high-performing team cultures.

Mr McDonnell has held numerous senior leadership positions at top pharmaceutical companies, including Pharmion and CSL Vifor. James spent time in the US as Head of Global Marketing at Pharmion, eventually acquired by Celgene Corporation for $2.9 billion, where his role involved leading a global marketing team in oncology and hematology markets, driving the growth and success of the portfolio while also contributing as the commercialization representative on the development committee. Most recently, he served as the Global Commercial Lead for Patient Blood Management at CSL Vifor, where he collaborated with the global enterprise taskforce to develop a comprehensive PBM strategy. His role at Vifor Pharma as Vice President, General Manager for Australia and New Zealand, saw him manage a broad portfolio including nanomedicines, nephrology, iron deficiency, and rare diseases, achieving substantial revenue growth while demonstrating an ability to navigate access challenges.

Mr McDonnell is a registered pharmacist in Australia and a member of the Royal Pharmaceutical Society. He has a Graduate Diploma in Marketing from Monash University and is a graduate of the Australian Institute of Company Directors.

Mr Steven Engle, Non-Executive Chair of the Company, commented, "On behalf of the Board, I am delighted to welcome James McDonnell as the new CEO of Prescient Therapeutics. The Board conducted a thorough selection process and is confident that James's strategic vision and leadership will significantly contribute to our ambitious development plans."

Commenting on his appointment, Mr McDonnell said: "It is an honour to join Prescient Therapeutics, a company with a remarkable history and a bright future. I am dedicated to leveraging my expertise in drug development and commercialisation to advance Prescient's innovative therapies, bringing them to market, and diversifying treatment options for patients. I look forward to working with the Board and team to drive long-term value for the Company and its shareholders."

A summary of the material terms of Mr McDonnell's employment agreement is included at Annexure A.

The Board of Prescient Therapeutics Limited has approved the release of this announcement.

– Ends –

To stay updated with the latest company news and announcements, please update your details on our investor centre.

About Prescient Therapeutics Limited (Prescient)

Prescient Therapeutics (ASX: PTX) is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies.

Targeted Therapy

PTX-100 is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). It disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral circuits in cancer cells, leading to apoptosis (death) of cancer cells. PTX-100 is believed to be the only GGT-1 inhibitor in the world in clinical development. PTX-100 demonstrated safety and early clinical activity in a previous Phase 1 study and recent PK/PD basket study of hematological and solid malignancies. PTX-100 is now in a Phase 1b expansion cohort study in T cell lymphomas, where it is showing encouraging efficacy and safety. The US FDA has granted PTX-100 Orphan Drug Designation for all T Cell Lymphomas. A Phase 2 study is in planning.

Cell Therapy Platforms

CellPryme-M: Prescient's novel, ready-for-the-clinic, CellPryme-M technology enhances adoptive cell therapy performance by shifting T towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumours. CellPryme-M is a 24-hour, non-disruptive process during cell manufacturing. Cell therapies that could benefit from additional productivity in manufacturing or increased potency and durability in-vivo, would be good candidates for CellPryme-M.

CellPryme-A: CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumour microenvironment. CellPryme-A significantly decreases suppressive regulatory T cells; increases expansion of CAR-T cells in vivo; increases tumour penetration of CAR-T cells. CellPryme-A improves tumour killing and host survival of CAR-T cell therapies, and these benefits are even greater when used in conjunction with CellPryme-M pre-treated CAR-T cells.

OmniCAR: is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product. OmniCAR's modular CAR system decouples antigen recognition from the T-cell signalling domain. It is the first universal immune receptor allowing post-translational covalent loading of binders to T-cells. OmniCAR is based on technology licensed from Penn; the SpyTag/SpyCatcher binding system licensed from Oxford University; and other assets. OmniCAR is in pre-clinical development.

The targeting ligand can be administered separately to CAR-T cells, creating on-demand T-cell activity post infusion and enables the CAR-T to be directed to an array of different tumour antigens. OmniCAR provides a method for single-vector, single cell product targeting of multiple antigens simultaneous or sequentially, whilst allowing continual re-arming to generate, regulate and diversify a sustained T-cell response over time.

Find out more at www.ptxtherapeutics.com or connect with us via Twitter @PTX_AUS and LinkedIn.

For more information please contact:

Company enquiries		**Investor enquiries**
Steve Engle	Steven Yatomi-Clarke	Christian Riedel
Chair	CEO & Managing Director	Reach Markets
Prescient Therapeutics	Prescient Therapeutics	1300 805 795
sengle@ptxtherapeutics.com	steven@ptxtherapeutics.com	ir@reachmarkets.com.au

Disclaimer and Safe Harbor Statement

Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited ("Prescient" or the "Company"), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words 'estimate', 'project', 'intend', 'expect', 'plan', 'believe', 'guidance', and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on our management's current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, global pandemics and related disruptions, the impact of pharmaceutical industry development and health care legislation in the United States and internationally, and challenges inherent in new product development. In particular, there are substantial risks in drug development including risks that studies fail to achieve an acceptable level of safety and/or efficacy. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Prescient only as of the date of this announcement. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this document, including, without limitation, statements containing the words "believes," "plans," "expects," "anticipates," and words of similar import, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties

and other factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any of its contents may be used for any other purpose without the prior written consent of the Company.

Supplemental COVID-19 Risk Factors

Please see our website: Supplemental COVID-19 Risk Factors

ANNEXURE A

The Company confirms that the material terms of the employment agreement between Mr McDonnell and the Company for the role of Chief Executive Officer are as follows:

Position Title	Chief Executive Officer
Commencement Date	20 January 2025
Fixed Remuneration	Fixed remuneration will be $390,250 per annum including statutory superannuation contribution.
Options Offer	Mr McDonnell will be eligible to receive unlisted options upon his acceptance of the employment agreement. The terms of the unlisted options are set out below: 24,000,000 unlisted options to vest in four equal tranches as follows: • 25% to vest 12 months following the issue date; • 25% to vest 24 months following the issue date; • 25% to vest 36 months following the issue date; • 25% to vest 48 months following the issue date. The final date and time for exercise of the unlisted options is 5pm (AEST) 5 years from the date of grant. If such date falls on a day that is not a Business Day, the final date will be the preceding Business Day. The exercise price for the unlisted options will be a price calculated at a 75% premium to the 5-day Volume Weighted Average Market Price of the Company's shares (5 Day VWAP) for the 5 ASX trading days immediately prior to, and including, the date of grant.
Short-Term Incentives	Mr McDonnell will be eligible to receive an annual bonus of up to 30% of base salary based on the achievement of agreed priorities between Mr McDonnell and the Board.
Long-Term Incentives	Mr McDonnell will be eligible to participate in any long-term incentive arrangements operated or introduced by the Company from time to time, in accordance with the terms and conditions governing those arrangements.
Termination	Termination of employment by either party with 6 months' written notice.